-+ 0.00%
-+ 0.00%
-+ 0.00%

4D Molecular Therapeutics posts corporate presentation highlighting 4D-150 retinal gene therapy program

PUBT·05/07/2026 20:46:33
Listen to the news
4D Molecular Therapeutics posts corporate presentation highlighting 4D-150 retinal gene therapy program
  • 4D Molecular Therapeutics investor presentation reiterated lead program 4D-150, an intravitreal AAV gene therapy designed for durable retinal expression of aflibercept as a backbone treatment for wet age-related macular degeneration and diabetic macular edema.
  • Global Phase 3 program outlined for wet AMD and DME, targeting a shift from frequent bolus anti-VEGF injections to long-term disease control.
  • PRISM Phase 2b data highlighted mean 1.0 supplemental anti-VEGF injections through 1 year in 3E10 vg/eye arm, implying average dosing interval of about 365+ days.
  • Market sizing cited $16 billion global branded retinal vascular disease anti-VEGF market in 2025E, including about $10 billion wet AMD and about $4 billion DME.
  • Pipeline summary also listed 4D-710 for cystic fibrosis lung disease as fully funded, 4D-725 for A1AT lung disease as fully funded through IND, and 4D-175 for geographic atrophy with an open IND while evaluating strategic funding alternatives.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.